Showcasing a range of digital neurotechnologies to improve the research, diagnosis and treatment in Alzheimer's disease.
Computerised testing brings an unprecedented ability to capture more detailed information about patient responses. This could provide novel insights into cognitive processes, and greater discriminatory power in predicting cognitive deficits and decline in Alzheimer's and other diseases.
The 2017 CANTAB Research Grant was once again overwhelmed with applications. All the research proposals received were such high quality it was another impossible task for our funding committee to review and narrow the proposals down. We received applications from across the globe from Hong Kong to Saint Lucia. But there could only be three awards.
Takeda and Cognition Kit partner to pilot wearables in patients with Major Depressive Disorder (MDD)
Takeda Pharmaceuticals U.S.A. and Cognition Kit Limited announce a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD).
Research using animals has long played an important role in neuroscience research and in the development of treatments for mental health and neurological disorders. Using CANTAB to assess cognition in human studies can be an important component of implementing the same guiding principles across species.
When assessing cognitive function, tests that are reliable, time and cost efficient and are comparable across cultures and languages are the key to producing accurate and valid results. There are various cognitive assessment tools out there, but what are the benefits of using language and culture independent touchscreen tests such as CANTAB?